# Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC

> **NCT04153734** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Kobe Minimally Invasive Cancer Center** · enrollment: 21 (estimated)

## Conditions studied

- Locally Advanced Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Cis Platinum
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed
- **DRUG:** nab paclitaxel

## Key facts

- **NCT ID:** NCT04153734
- **Lead sponsor:** Kobe Minimally Invasive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2019-12-01
- **Primary completion:** 2021-11-30
- **Final completion:** 2023-11-30
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2019-11-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04153734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04153734, "Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT04153734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*